- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.07. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | iSpecimen Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| ISPECIMEN Aktie jetzt für 0€ handeln | |||||
| 27.06. | iSpecimen Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 24.06. | iSpecimen gibt Änderungen im Vorstand und neue Direktorenernennung bekannt | 1 | Investing.com Deutsch | ||
| 24.06. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | iSpecimen Inc. - S-1/A, General form for registration of securities | 10 | SEC Filings | ||
| 05.06. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.05. | iSpecimen Inc. - S-1/A, General form for registration of securities | 4 | SEC Filings | ||
| 19.05. | iSpecimen Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | iSpecimen Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 4 | SEC Filings | ||
| 02.05. | iSpecimen Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 14.04. | iSpecimen Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | iSpecimen Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 11.03. | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.02. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.01. | iSpecimen Inc.: iSpecimen Secures Suppliers for COVID-style hMPV Outbreak | 461 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - January 16, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, has secured suppliers for the flu-like human metapneumovirus... ► Artikel lesen | |
| 20.12.24 | iSpecimen Inc.: iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens | 410 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025... ► Artikel lesen | |
| 13.12.24 | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | 991 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| 13.12.24 | iSpecimen Inc.: iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers | 349 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 12.12.24 | iSpecimen Inc.: iSpecimen Appoints Robert Lim as CEO and Director | 601 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 12, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ILLUMINA | 81,67 | -1,28 % | Illumina Stock: What Went Wrong And Why It's Best To Stay Away | ||
| CRISPR THERAPEUTICS | 55,50 | -0,89 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| INTELLIA THERAPEUTICS | 10,890 | +4,91 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| EDITAS MEDICINE | 2,700 | +13,88 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 112,10 | -1,32 % | NBIX: Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients | WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) shared new results from a one-year clinical study at the Endocrine Society's 2025 Annual Meeting in San Francisco. The study looked... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 12,600 | -12,56 % | Arrowhead hits the skids due to partnership with Sarepta | ||
| GALAPAGOS NV | 27,240 | +1,64 % | Galapagos NV: Galapagos Appoints Aaron Cox as Chief Financial Officer | Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership
Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 3,380 | -8,15 % | Cardiff Oncology vor Entscheidung: Die spannendste Krebs-Aktie! | Es ist der gewohnte Raketenstart nach Maß: Unser neuer Community-Tipp Cardiff Oncology legt furios los, gewinnt allein seit unserer Enthüllung im Live Chat vor genau einer Woche über 20% an Wert. Und... ► Artikel lesen | |
| TWIST BIOSCIENCE | 29,500 | -2,48 % | Cathie Wood setzt wieder auf Nvidia, auch TSMC wandert verstärkt ins Portfolio, mit Twist Bioscience wird eine Wette eingegangen und Palantir scheint der Investorin zu heiß geworden | Die Börse wird oft als seriöser und kühler Ort angesehen, doch sind die Handelsplätze längst nicht frei von Emotionen. Auch hier gibt es prominente Investorinnen und Investoren, die teils wie Popsternchen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,380 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| REPLIGEN | 100,85 | +0,87 % | Repligen Corporation: Repligen to Report Second Quarter 2025 Financial Results | ||
| ROCKET PHARMACEUTICALS | 2,690 | +2,99 % | Rocket Pharmaceuticals stock surges after FDA grants key designation | ||
| XBIOTECH | 2,540 | -0,78 % | XBiotech beruft Thomas Kündig und Craig Rademaker in den Vorstand | ||
| PERSONALIS | 5,270 | -0,85 % | Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer | ||
| SPERO THERAPEUTICS | 1,982 | -3,32 % | Sports Injuries Made Every Day a Mortal Struggle Until The Spero Clinic Began Treatment: Kole Jackson's Story | FAYETTEVILLE, ARKANSAS / ACCESS Newswire / July 7, 2025 / With around 30 million children participating in organized sports in the U.S., almost all of them will experience some kind of injury while... ► Artikel lesen |
Das Unternehmen ISPECIMEN INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISPECIMEN INC finden Sie auf Wallstreet Online.